Coronavirus / COVID

Trial to enroll up to 30000 volunteers across approximately 115 sites in the US and Mexico.

With the public beginning to get vaccinated, CDC published information for people in some medical categories and considerations on severe allergic reactions.

Between March 1 and July 31, there were 76088 deaths among Americans aged 25 to 44, amounting to 11899 (18.5%) more than expected during that timeframe, new research shows.

The new COVID-19 variant, B.1.1.7, continues to make its way around Europe and the world with new cases.

A new study from Italy provides evidence that new mothers with COVID-19 can safely breastfeed and stay together in the same room with their newborns after delivery if they follow safety precautions.

Vaccine manufacturer Valneva recently announced it was initiating a phase 1/2 trial in the United Kingdom.

Anti-COVID-19 nanobodies may potentially be effective at preventing and diagnosing infections.

Phase 3 trial data shows experimental monoclonal antibody not to be efficacious.

While ACE2 expression has been reported in the human brain, the cell-specific expression pattern of ACE2 is unknown.

The agreement could mean upwards of 70 million more doses for eligible patients in mid-2021.

Characterizing SARS-CoV-2 interactions can improve understanding of viral RNA functions and the host innate immune response.

Regional and national decision-making can be informed by the online model, called the COVID-19 Pool Tool.

Though research is pending, the CEO used simple science to explain why the mRNA vaccine may still prevent from the UK variant.

The study helps to illuminate how spike proteins initiate infections.

Countries across Europe are reinstating travel bans and lockdowns to combat virus.

A new case series report highlights the unique circumstances of infant illness associated with COVID-19.

New data suggests informed, practical pooled testing could improve both public health response and clinical assessment of the pandemic.

Healthcare providers may want to consider these risks when determining which COVID-19 patients could benefit the most from the new monoclonal antibody therapies.

The VRBPAC voted 20-0 with 1 abstention to support the benefit-risk profile associated with mRNA-1273.

The authors note that the difference in hospitalization rate may be partly due to existing immunity to influenza in the population.

Regimen reduces mortality and recovery time in patients severely ill with pneumonia caused by the virus.

At the interim analysis, the mRNA-1273 vaccine was found to have an efficacy of 94.5% against confirmed COVID-19.

Review of data in trial registries shows they specifically excluded this group from studies involving therapies.

Up to 40% more doses—or, enough to vaccinate another person with two doses—has been observed in the vials distributed at the beginning of this week.